Sunitinib Benefit Explored in advanced Kidney Cancer
Research shows that the targeted cancer drug sunitinib (SUTENT) has shown promising results in advanced kidney cancer patients who have a poor prognosis. — HealthDay News (Thursday, July 16)
Previous clinical trials showed that sunitinib was effective in advanced kidney cancer patients, and according to background information with the study, the drug has been approved worldwide as a first and second line treatment for these patients. However, little is known about the activity of the drug in advanced kidney cancer patients with poor prognosis, such as those patients whose cancer has spread to brain, those with poor performance status, and the elderly.
The new study published online and in the August print issue of The Lancet Oncology, included 4,564 advanced kidney cancer patients with poor prognosis in 52 countries, these patients were divided into 4 subgroups: patients with brain metastases, non-clear-cell RCC, poor performance status, and patients aged 65 and older.
All of the patients received 50 milligrams of sunitinib once daily, repeated in six-week cycles (four weeks on treatment followed by two weeks off treatment). HOW TO TAKE SUTENT. The researchers assessed tumor response, toxicity, and adverse events at regular intervals.
The study authors reported that the median progression-free survival was 10.9 months, and overall survival was 18.4 months, which was an improvement over previous findings. In the four subgroups, the response rates were: brain metastases, 12%; non-clear-renal cell carcinoma, 11%; poor performance status, 9%; and elderly, 17%; with an overall objective response rate of 17%. and also the study authors noted that, Overall, the study found that the drug can be given safely and is well-tolerated in all four subgroups. Diarrhea (44%) and fatigue (37%) were the most common treatment-related adverse events. (POSSIBLE SIDE EFFECTS OF SUTENT)
The safety and efficacy of sunitinib in an older population are confirmed and evidence shows that age alone should not be a deterrent from attempting therapy. — experts added In an article accompanying the study.
But “patients with brain metastases, non-clear-cell histology, and poor performance status benefit less from sunitinib, despite good drug tolerance, suggesting the need for prospective studies in these subpopulations,” wrote Dr. Joaquim Bellmunt of Hospital del Mar in Barcelona, Spain, and the Dana-Farber Cancer Institute and Harvard Medical School in Boston, and Dr. Toni K. Choueiri of Dana-Farber and Harvard.
“Thus, claiming sunitinib as a ’standard’ in these subgroups remains controversial. An oncologist might not have access to such trials in practice, however, and based on available information the use of sunitinib may be justified in these subpopulations,” they concluded.
SOURCE: The Lancet Oncology, news release, July 15, 2009
[...] extensive imaging tests have shown no other evidence of cancer spread. Otherwise, treatment with targeted therapiesor cytokine immunotherapy will be recommended. Clinical trials of new treatments are an option as [...]